2 weeks Ago By Defense World Staff
Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER – Free Report) in a research report sent to investors on Tuesday,Benzinga reports.A number of other brokerages have also commented on OMER. StockNews.
com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $36.
00 target price on shares of Omeros in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Omeros currently has an average rating of “Moderate Buy” and an average price target of $22.
50.Read Our Latest Research Report on OMEROmeros Price PerformanceOMER opened at $7.91 on Tuesday.
Omeros has a one year low of $2.61 and a one year high of $13.60.
The business has a 50 day simple moving average of $8.64 and a two-hundred day simple moving average of $7.61.
The firm has a market capitalization of $458.38 million, a price-to-earnings ratio of -3.42 and a beta of 2.
03. Institutional Inflows and OutflowsA number of large investors have recently added to or reduced their stakes in the stock. Truvestments Capital LLC increased its holdings in shares of Omeros by 116.
5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Omeros by 79.
0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP bought a new stake in Omeros during the 4th quarter valued at about $46,000.
Picton Mahoney Asset Management raised its holdings in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 4,404 shares during the last quarter.
Finally, US Bancorp DE bought a new position in shares of Omeros in the fourth quarter worth approximately $81,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.
Omeros Company Profile (Get Free Report)Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.See AlsoFive stocks we like better than Omeros5 Top Rated Dividend Stocks to ConsiderD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyHow to Calculate Stock Profit Amazon Falls Back to a Key Support Line: Here’s How to Play ItHow to Evaluate a Stock Before Buying Buffett Trims Equities, But Still Keeps Buying This Stock.
